Tubular PFKFB3 drives diabetic kidney fibrosis via lactate‑dependent H4K12 lactylation and HIPK2 transactivation
Authors:
Open Access
- 13 July 2026
- journal article
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 58 (3) , 1-13
Abstract
Aerobic glycolysis is increasingly recognized as a pathogenic driver in diabetic kidney disease (DKD). However, the epigenetic role of its end product, lactate, remains largely undefined. Spatial transcriptomics analysis revealed active glycolysis in tubular epithelial cells. The participation of histone lactylation in DKD was confirmed through inhibition of histone lactylation by glycolysis inhibitors or lactate in vivo. The potential target genes of H4K12 lactylation (H4K12la) were screened by CUT&Tag analyses. The candidate target genes were validated through ChIP‑qPCR, RT‑qPCR and western blot analyses. The present study found that the expression of 6‑phosphofructo‑2‑kinase/fructose‑2,6‑biphosphatase 3 (PFKFB3), a pivotal glycolytic regulator, was markedly upregulated in tubular epithelial cells derived from patients with DKD and from the corresponding mouse models. Inhibition of the expression of PFKFB3 mitigated the kidney fibrotic process and alleviated renal function in a DKD mouse model. Conversely, upregulation of PFKFB3 expression aggravated renal fibrogenesis and promoted the deterioration of renal pathology. Moreover, it was demonstrated that the reduction in the levels of lactate levels markedly alleviated renal fibrosis in DKD. With regard to its mechanism of action, lactate was generated via PFKFB3‑driven glycolytic reprogramming and selectively enhanced H4K12 lactylation at the homeodomain‑interacting protein kinase 2 (HIPK2) promoter, thereby activating its transcription and driving renal fibrotic progression. These findings indicated that PFKFB3 in renal tubules upregulates HIPK2 expression via facilitating H4K12la‑dependent gene transcription. Therefore, intervention approaches targeting PFKFB3‑triggered HIPK2 activation in tubular cells may offer a novel therapeutic strategy for DKD.Keywords
This publication has 53 references indexed in Scilit:
- FABP4 inhibition protects renal tubular cells and ameliorates renal inflammation in diabetic kidney diseaseBiochemical Pharmacology, 2025
- SIRT3 deficiency reduces PFKFB3-driven T-cell glycolysis and promotes arthritic inflammationScience China Life Sciences, 2025
- Lgals3 Promotes Calcium Oxalate Crystal Formation and Kidney Injury Through Histone Lactylation‐Mediated FGFR4 ActivationAdvanced Science, 2025
- Deletion of Pyruvate Carboxylase in Tubular Epithelial Cell Promotes Renal Fibrosis by Regulating SQOR/cGAS/STING‐Mediated GlycolysisAdvanced Science, 2025
- Efficacy and Safety of Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes By Diuretic Use: A FIDELITY AnalysisEuropean Journal of Heart Failure, 2025
- Lactylation modification in cardio-cerebral diseases: A state-of-the-art reviewAgeing Research Reviews, 2024
- Tubular MYDGF Slows Progression of Chronic Kidney Disease by Maintaining Mitochondrial HomeostasisAdvanced Science, 2024
- Astragaloside IV protects renal tubular epithelial cells against oxidative stress‐induced injury by upregulating CPT1A‐mediated HSD17B10 lysine succinylation in diabetic kidney diseasePhytotherapy Research, 2024
- Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patternsDiabetologia, 2024
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001